Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats

Drug Metabolism and Disposition

Volumn 24, Issue 3, 1996, Pages 288-292

  Martin, Ulrich ^a   Doerge, Liesel ^a   Stegmeier, Karlheinz ^a   Müller Beckmann, Bernd ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INULIN; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; INULIN CLEARANCE; KIDNEY FAILURE; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; FIBRINOLYTIC AGENTS; INULIN; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MALE; PLASMINOGEN ACTIVATORS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029874648     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. U. Kohnert, R. Rudolph, J. H. Verheijen, E J. D. Weening-Verhoeff, A. Stern, U. Opitz, U. Martin, H. Lill, H. Prinz, M. Lechner, G. B. Kresse, P. Buckel, and S. Fischer. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng. 5, 93-100 (1992).
2. U. Martin, S. Fischer, U. Kohnert, R. Rudolph, G. Sponer, A. Stern, and K. Strein: Pharmacokinetic properties of an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. Thromb. Res. 62, 137-146 (1991).
3. U. Martin, J Köhler, G. Sponer, and K. Strein: Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 6, 39-13 (1992).
4. U. Martin, E. von Möllendorf, W Akpan, R. Kientsch-Engel, B Kaufmann, and G. Neugebauer: Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb. Haemostas. 66, 569-574 (1991).
5. E Seifried, M M, Muller, U. Martin, R. König, and V. Hombach: Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects on the hemostatic system. Ann. N.Y. Acad. Sci. 667, 417-420 (1992).
6. K. L. Neuhaus, R. von Essen, A. Vogt, U. Tebbe, J. Rustige, H.-J. Wagner, K.-F. Appel, U. Stienen, R König, W. Meyer-Sabellek: Dose finding with a novel recombinant plasminogen activator (BM 06.022) in pa-dents with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. J. Am. Coll. Cardiol. 24, 55-60 (1994).
7. R. W Smalling, C. Bode, J Kalbfleisch, S. Sen, P. Limbourg, F. Forycki, G. Habib, R. Feldman, S. Hohnloser, A. Seals, and the RAPID Investigators: More rapid, complete, and stable coronary chrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 91, 2725-2732 (1995).
8. C. Bode, R. W. Smalling, J. Kalbfleisch, G. Berg, D. J. Odenheimer, E. Boehm, and W. D. Weaver: Randomized comparison of double bolus reteplase (rPA) and front-loaded alteplase (rt-PA) in myocardial infarction patients (RAPID II). Eur. Heart J. 16 (Suppl.). 11 (abstr.) (1995).
9. U. Martin, G. Sponer, and K. Strein: Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. Drug Metab. Dispos. 21, 236-241 (1993).
10. J. Kuiper, H. van der Bilt, U. Martin, T. J. C. van Berkel: Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. Thromb. Haemostas. 74, 1501-1510 (1995).
11. D. C. Rijken, E. Groeneveld, and M. M. Barrett-Bergshoeff: In vitro stability of a tissue-type plasminogen activator mutant. BM 06.022, in human plasma. Thromb. Haemostas. 72, 906-911 (1994).
12. N. Gretz: "Vergleich zweier Urämiemodelle bei der Ratte: Nierenteilresektion versus Ligatur von Nierenanerienäsien." Habilitationsschrift, Universitat Heidelberg, Germany, 1991.
13. W. B. Waynforth: "Experimental and Surgical Technique in the Rat," pp. 159-160. Academic Press, London, 1988.
14. H. O. Beutler: Inulin. In "Methods of Enzymatic Analysis" (H. U. Bergmeyer, ed.), pp. 41-45. Verlag Chemie, Weinheim, 1984.
15. J. H. Verheijen, E. Mullaarrt G. T. G. Chang, C. Kluft, and G. Wijngaards: A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb. Haemostas. 48, 266-269 (1982).
16. M. Nishiuchi, K. Kai, Y. Takagishi, M. Notoya, H. Hasegawa, K. Sugeno, V. Mizuhira. and H. Yamada: Disposition of S-6820 (recombinant human interleukin-2) in rats-metabolism of S-6820 in the kidney. J. Pharmacobiodyn. 14, s-36 (1991).
17. G. R. Larsen, M. Metzger, K. Henson, Y. Blue, and P. Horgan: Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in the rat Blood 73, 1842-1850 (1989).
18. E. Passamani, M. Hodges, M. Herman, R. Grose, B. Chaitman, W. Rogers, S. Forma, M. Terrin, G. Knatternd, T. Robenson, E. Braunwald, for the TIMI Investigators: The Thrombolysis in Myocardial Infarction (TIMI) Phase II Pilot Study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J. Am. Coll. Cordial. 10, 51B-64B (1987).
19. H. E. Fuchs, H. Berger, Jr., and S. V. Pizzo: Catabolism of human tissue-type plasminogen activator in mice. Blood 65, 539-544 (1985).
20. J. J. Emeis, C. M. van den Hoogen, and D. Jense: Hepatic clearance of tissue-type plasminogen activator in rats. Thromb. Haemostas. 54, 661-664 (1985).
21. S. Nilson, M. Einarsson, S. Ekvarn, L. Haggroth, and C. Mattson: Turnover of tissue type plasminogen activator in normal and hepatectomized rabbits. Thromb. Res. 39, 511-521 (1985).
22. T. Nilsson, P. Wallén, and G. Mellbring: In vivo metabolism of human tissue-type plasminogen activator. Scand. J. Haematol. 33, 49-53 (1985).